主页 > 医学讨论 >
【medical-news】Losartan减少高血压丙型肝炎患者发生
NEW YORK (Reuters Health) Aug 20 - Treatment with losartan reduces the risk of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C, according to researchers.
"Data supporting a link between type 2 diabetes mellitus and chronic hepatitis C infection have been reported," Dr. Yasuji Arase at Toranomon Hospital in Tokyo and colleagues write in the September Journal of Medical Virology.
On the basis of earlier reports that angiotensin receptor antagonists can improve insulin sensitivity and glucose and lipid metabolism, the researchers analyzed the cumulative incidence and predictive factors for type 2 diabetes in 80 patients with hepatitis C virus (HCV) infection and hypertension who were treated with losartan. Another 160 patients treated with spironolactone and matched for age and gender served as controls.
At a mean follow-up of slightly more than 5 years, 3 losartan patients and 22 spironolactone patients had developed type 2 diabetes. The fifth-year cumulative appearance rate of type 2 diabetes was 5.9% in the losartan group and 14.0% in the spironolactone group, according to the authors.
On multivariate analysis, hazard ratios for development of type 2 diabetes were 6.10 with spironolactone, 4.31 when histological staging was advanced, 3.28 with steatosis, and 2.47 with pre-diabetes.
"Our results indicate losartan causes about 60% reduction of the risk of type 2 diabetes development compared to spironolactone," the authors said.
Vascular events occurred in 2 losartan-treated patients and 6 spironolactone-treated patients during the observation period.
J Med Virol 2009;81:1584-1590. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 Losartan Lowers Diabetes Risk in Patients With Hypertension and HCV
洛沙坦可降低高血压以及丙肝患者糖尿病发生几率
NEW YORK (Reuters Health) Aug 20 - Treatment with losartan reduces the risk of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C, according to researchers.
纽约（路透社健康频道）8月20日报道---研究人员称应用洛沙坦可以降低日本高血压及慢性丙肝患者二型糖尿病发病几率。
"Data supporting a link between type 2 diabetes mellitus and chronic hepatitis C infection have been reported," Dr. Yasuji Arase at Toranomon Hospital in Tokyo and colleagues write in the September Journal of Medical Virology.
东京虎门医院的Yasuji Arase及其同事在九月份的医学病毒学杂志上称“有研究数据表明二型糖尿病往往与丙肝病毒感染有关。”
On the basis of earlier reports that angiotensin receptor antagonists can improve insulin sensitivity and glucose and lipid metabolism, the researchers analyzed the cumulative incidence and predictive factors for type 2 diabetes in 80 patients with hepatitis C virus (HCV) infection and hypertension who were treated with losartan. Another 160 patients treated with spironolactone and matched for age and gender served as controls.
在以前关于血管紧张素受体激动剂可以增强胰岛素敏感性并可增加糖脂代谢的研究报道基础上，研究人员分析80位应用洛沙坦治疗的合并丙肝病毒感染的高血压患者二型糖尿病的累积发病率及其影响因素。另外160名年龄性别性匹配患者应用螺内酯作为对照。
At a mean follow-up of slightly more than 5 years, 3 losartan patients and 22 spironolactone patients had developed type 2 diabetes. The fifth-year cumulative appearance rate of type 2 diabetes was 5.9% in the losartan group and 14.0% in the spironolactone group, according to the authors.
平均随访5年以上，三名应用洛沙坦的患者以及22名应用螺内酯的患者出现了二型糖尿病。作者说5年二型糖尿病的累积发生率，洛沙坦组为5.9%，螺内酯组为14.0%。
On multivariate analysis, hazard ratios for development of type 2 diabetes were 6.10 with spironolactone, 4.31 when histological staging was advanced, 3.28 with steatosis, and 2.47 with pre-diabetes.
多因素分析发现，二型糖尿病发病危险因素螺内酯组为6.10。其中4.31出现病理学改变3.28出现脂肪变性同时2.47出现前驱期糖尿病。（是百分之吧，不确定）
"Our results indicate losartan causes about 60% reduction of the risk of type 2 diabetes development compared to spironolactone," the authors said.
作者说：“我们的结果表明与螺内酯组相比洛沙坦可以降低60%二型糖尿病的发生风”
Vascular events occurred in 2 losartan-treated patients and 6 spironolactone-treated patients during the observation period.
有2例洛沙坦组患者及6例螺内酯组患者观察期间出现心血管疾病发病。 纽约（路透社健康频道）8月20日报道---研究人员称应用洛沙坦可以降低日本高血压及慢性丙肝患者二型糖尿病发病几率。
东京虎门医院的Yasuji Arase及其同事在九月份的医学病毒学杂志上称“有研究数据表明二型糖尿病往往与丙肝病毒感染有关。”
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-06 17:11
医学,生命科学网